A 79-Year-Old Woman With Multiple Myeloma

Clifton C. Mo, MD, provides insight on the management of multiple myeloma and evaluates the role of current treatment regimens.

EP. 1: Case Overview: 79-Year-Old Woman With Multiple Myeloma

April 26th 2021

Clifton C. Mo, MD, presents the case of a 79-year-old woman with R-ISS stage I multiple myeloma and shares his initial impressions.

EP. 2: Frontline Treatment Options for Multiple Myeloma

April 26th 2021

An expert hematologist-oncologist reviews the standard of care for transplant-eligible and transplant-ineligible patients with newly diagnosed MM and explores the role of quadruplet induction regimens.

EP. 3: Second-Line Treatment Options for Multiple Myeloma

April 26th 2021

Dr Clifton Mo describes second-line treatment options for the management of multiple myeloma, and treatment approaches for IMiD- and anti-CD38–refractory MM.

EP. 4: Phase 3 BOSTON Trial for RRMM

April 26th 2021

An expert hematologist-oncologist reviews the randomized, phase 3 BOSTON trial of a selinexor-based triplet regimen for the treatment of multiple myeloma.

EP. 5: Phase 1 STOMP Trial for RRMM

April 26th 2021

Clifton C. Mo, MD, reviews the ongoing multicenter phase 1 STOMP trial in relapsed/refractory multiple myeloma.

EP. 6: Role of Toxicity Management in RRMM

April 26th 2021

An expert hematologist-oncologist provides his perspective on the importance of managing toxicities in patients with relapsed/refractory multiple myeloma.

EP. 7: Future Treatment Landscape for RRMM

April 26th 2021

Multiple myeloma expert, Dr Clifton Mo, shares his insights on future directions for the treatment of multiple myeloma.